Global

Leela Barham looks at the reasons behind the Association of the British Pharmaceutical Industry's bid to legally challenge NICE's proposed introduction of the budget impact test.

With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.

Reflector asks if the UK's newly announced post-Brexit life sciences strategy report is worth a look as a springboard to addressing future EU ties in healthcare, or just more bluster?

Leela Barham casts her eye over the UK's plans for its life sciences industry in the post-Brexit world.

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

With a new consultation from the UK’s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines, what could this mean for negotiation of a successor to the 2014 Pharmaceutical Price Regulation Scheme (PPRS)? Leela Barham reports.

Indonesia, once considered by global investors as Asia’s “greatest underachiever,” is showing signs of an economic resurgence, nowhere more apparent than in the country’s pharmaceuticals sector.

Time will determine the shape of biosimilar usage in oncology, but they will play a significant role in the battle against cancer in the future, writes Alessandra Franceschetti.

The UK is entering into unchartered waters between Brexit – offering potentially new approaches to procurement – and negotiating a successor to the PPRS. The government's new recruit Steve Oldfield could give it the inside track, writes Leela Barham.

Tensions are becoming clear within industry as it faces what might yet be the toughest negotiations on pricing with the UK government. Leela Barham reports.

Value frameworks are now "sexy". In the US, no fewer than five have emerged since around 2015. Leela Barham discusses how the value assessment landscape is evolving.

The Association of the British Pharmaceutical Industry is seeking permission for a Judicial Review of NICE's affordability proposals. Leela Barham reports.

Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

Lana Sinichkina, Kateryna Oliinyk and Yevgeniya Ocheretko discuss how the recent settlement between Gilead and Ukraine's Ministry of Health could promote earlier market access in the country.

Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.